The impact of BMI on long-term anthropometric and metabolic outcomes in girls with idiopathic central precocious puberty treated with GnRHas.
body mass index
central precocious puberty
child
final height
gonadotropin-releasing hormone analogues
insulin resistance
lipids
obesity
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
07
2022
accepted:
07
09
2022
entrez:
20
10
2022
pubmed:
21
10
2022
medline:
22
10
2022
Statut:
epublish
Résumé
Gonadotropin-releasing hormone analogs (GnRHas) are effective in increasing the final height of children with idiopathic central precocious puberty (ICPP). However, in previous years, some transient metabolic complications have been described during this treatment, for which there are no long-term outcome data. Our study aimed to evaluate the efficacy of GnRHas and clarify if body mass index (BMI) at diagnosis of ICPP could influence long-term outcomes. This was an observational, retrospective study that recruited a cohort of girls with ICPP. Data for anthropometric measures, fasting lipid profile, and glucose metabolism were collected at baseline [when GnRHas treatment started (T1)], at the end of the treatment (T2), and near-final height (nFH) or final height (FH) (T3). Predicted adult height (PAH) was calculated at T1 following Bayley and Pinneau's method. Analysis was carried out using BMI standard deviation score (SDS) categories at T1 (group A, normal weight, vs. group B, overweight/obese). Fifty-seven girls with ICPP who were treated with GnRHas were enrolled in the study (group A vs. group B: 33 vs. 24 patients, aged 7.86 ± 0.81 vs. 7.06 ± 1.61 years, respectively; Our results confirm the effectiveness of treatment with GnRHas on growth and do not support the concern that being overweight and obese can impair the long-term outcomes of GnRHas therapy. However, the observed transient impairment of metabolic parameters during treatment suggests that clinicians should encourage ICPP girls treated with GnRHas to have a healthy lifestyle, regardless of their pretreatment BMI.
Sections du résumé
Background
Gonadotropin-releasing hormone analogs (GnRHas) are effective in increasing the final height of children with idiopathic central precocious puberty (ICPP). However, in previous years, some transient metabolic complications have been described during this treatment, for which there are no long-term outcome data. Our study aimed to evaluate the efficacy of GnRHas and clarify if body mass index (BMI) at diagnosis of ICPP could influence long-term outcomes.
Methods
This was an observational, retrospective study that recruited a cohort of girls with ICPP. Data for anthropometric measures, fasting lipid profile, and glucose metabolism were collected at baseline [when GnRHas treatment started (T1)], at the end of the treatment (T2), and near-final height (nFH) or final height (FH) (T3). Predicted adult height (PAH) was calculated at T1 following Bayley and Pinneau's method. Analysis was carried out using BMI standard deviation score (SDS) categories at T1 (group A, normal weight, vs. group B, overweight/obese).
Results
Fifty-seven girls with ICPP who were treated with GnRHas were enrolled in the study (group A vs. group B: 33 vs. 24 patients, aged 7.86 ± 0.81 vs. 7.06 ± 1.61 years, respectively;
Conclusions
Our results confirm the effectiveness of treatment with GnRHas on growth and do not support the concern that being overweight and obese can impair the long-term outcomes of GnRHas therapy. However, the observed transient impairment of metabolic parameters during treatment suggests that clinicians should encourage ICPP girls treated with GnRHas to have a healthy lifestyle, regardless of their pretreatment BMI.
Identifiants
pubmed: 36263328
doi: 10.3389/fendo.2022.1006680
pmc: PMC9574359
doi:
Substances chimiques
Gonadotropin-Releasing Hormone
33515-09-2
Lipoproteins, HDL
0
Glucose
IY9XDZ35W2
Cholesterol
97C5T2UQ7J
Lipids
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1006680Informations de copyright
Copyright © 2022 Bruzzi, Valeri, Sandoni, Madeo, Predieri, Lucaccioni and Iughetti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
West J Med. 2000 Mar;172(3):182-5
pubmed: 10734809
Pediatr Rep. 2012 Dec 6;4(4):e35
pubmed: 23355935
PLoS One. 2009 Dec 24;4(12):e8450
pubmed: 20041184
Arch Dis Child. 1969 Jun;44(235):291-303
pubmed: 5785179
Horm Res. 2002;57 Suppl 2:2-14
pubmed: 12065920
J Pediatr Endocrinol Metab. 2019 Feb 25;32(2):181-186
pubmed: 30699070
Ann Pediatr Endocrinol Metab. 2017 Mar;22(1):27-35
pubmed: 28443256
J Pediatr. 1952 Apr;40(4):423-41
pubmed: 14918032
Pediatr Endocrinol Diabetes Metab. 2009;15(1):7-11
pubmed: 19454183
Ann Pediatr Endocrinol Metab. 2017 Jun;22(2):95-101
pubmed: 28690987
Int J Obes Relat Metab Disord. 2003 Aug;27(8):869-74
pubmed: 12861226
Eur J Endocrinol. 2010 Jul;163(1):55-62
pubmed: 20356934
J Clin Endocrinol Metab. 1998 Feb;83(2):370-3
pubmed: 9467543
Ann Pediatr Endocrinol Metab. 2017 Mar;22(1):49-54
pubmed: 28443259
Pediatrics. 2009 Apr;123(4):e752-62
pubmed: 19332438
J Endocrinol Invest. 2006 Jul-Aug;29(7):581-93
pubmed: 16957405
Horm Res Paediatr. 2012;78(5-6):304-11
pubmed: 23257624
Pediatrics. 2009 Jan;123(1):84-8
pubmed: 19117864
Int J Epidemiol. 2020 Jun 1;49(3):834-844
pubmed: 32372073
Int J Androl. 2006 Feb;29(1):272-7; discussion 286-90
pubmed: 16371114
J Clin Endocrinol Metab. 2010 Aug;95(8):3736-44
pubmed: 20484471
J Pediatr Endocrinol Metab. 2000 Jul;13 Suppl 1:709-15
pubmed: 10969913
Front Med. 2017 Jun;11(2):266-276
pubmed: 28500430
J Pediatr. 2003 Jun;142(6):643-6
pubmed: 12838192
Eur J Endocrinol. 2004 Apr;150(4):533-7
pubmed: 15080784
J Pediatr Endocrinol Metab. 2019 Dec 18;32(12):1369-1375
pubmed: 31605579
Children (Basel). 2022 Jan 14;9(1):
pubmed: 35053736
Obesity (Silver Spring). 2007 Nov;15(11):2825-31
pubmed: 18070774
Acta Biomed. 2009 Apr;80(1):21-8
pubmed: 19705616
Circulation. 2006 Sep 5;114(10):1056-62
pubmed: 16940191
Arch Dis Child. 1970 Dec;45(244):755-62
pubmed: 5491878
Ann Pediatr Endocrinol Metab. 2018 Mar;23(1):14-20
pubmed: 29609441
Eur J Endocrinol. 2012 Dec;167(6):733-47
pubmed: 22989465
Trends Endocrinol Metab. 2009 Jul;20(5):237-42
pubmed: 19541497
J Clin Endocrinol Metab. 2001 Jun;86(6):2863-8
pubmed: 11397901
J Clin Endocrinol Metab. 2014 Oct;99(10):3829-35
pubmed: 25029416
Pediatrics. 2008 Feb;121 Suppl 3:S208-17
pubmed: 18245513
J Clin Endocrinol Metab. 2015 Apr;100(4):1445-51
pubmed: 25650898
Helv Paediatr Acta. 1983 Aug;38(3):229-43
pubmed: 6618891
J Clin Endocrinol Metab. 2011 May;96(5):1393-401
pubmed: 21346077
Lancet Diabetes Endocrinol. 2022 May;10(5):351-365
pubmed: 35248172
Bull World Health Organ. 2007 Sep;85(9):660-7
pubmed: 18026621
J Clin Endocrinol Metab. 1981 Feb;52(2):370-2
pubmed: 6780592
Horm Res Paediatr. 2017 Apr 7;87(3):162-169
pubmed: 28391271
Acta Paediatr. 2009 Jun;98(6):1029-36
pubmed: 19292833
Endocr J. 1998 Jun;45(3):351-6
pubmed: 9790269
Int J Pediatr Endocrinol. 2014;2014(1):5
pubmed: 24742263
Nutrients. 2020 Jan 13;12(1):
pubmed: 31941004
Cell Metab. 2020 Dec 1;32(6):951-966.e8
pubmed: 33080217
Pediatr Obes. 2014 Aug;9(4):292-9
pubmed: 23713062
Acta Paediatr. 2007 Sep;96(9):1338-42
pubmed: 17718788
Int J Androl. 2006 Feb;29(1):247-55; discussion 286-90
pubmed: 16466546